FPRX - Five Prime Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.58
+0.08 (+0.70%)
At close: 4:00PM EST

11.58 0.00 (0.00%)
After hours: 4:48PM EST

Stock chart is not supported by your current browser
Previous Close11.50
Open11.58
Bid11.13 x 1800
Ask14.00 x 800
Day's Range11.49 - 11.82
52 Week Range7.84 - 22.75
Volume188,550
Avg. Volume368,364
Market Cap410.693M
Beta (3Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-4.05
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.57
Trade prices are not sourced from all markets
  • Markit10 hours ago

    See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

    Five Prime Therapeutics Inc NASDAQ/NGS:FPRXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderate for FPRX with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on February 13. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding FPRX totaled $2.84 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wire8 days ago

    Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019, after the U.S. financial markets close.

  • Business Wire11 days ago

    Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019 at 2:00 pm PT.

  • Why are deep-pocketed biotechs cutting hundreds of jobs?
    American City Business Journals16 days ago

    Why are deep-pocketed biotechs cutting hundreds of jobs?

    Biotech companies' reasons differ for 600 job cuts over the past few months, but the numbers are jarring for an industry at the intersection of a strong cash position and groundbreaking science.

  • MacroGenics Up on Lifting of Partial Hold on Cancer Candidate
    Zacks18 days ago

    MacroGenics Up on Lifting of Partial Hold on Cancer Candidate

    MacroGenics' (MGNX) shares rise as the FDA lifts partial clinical hold on its early-stage cancer candidate, MGD009, placed in December last year.

  • Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue?
    Zacks23 days ago

    Five Prime Therapeutics, Inc. (FPRX) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Five Prime Therapeutics, Inc. (FPRX).

  • Business Wire29 days ago

    Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that a poster entitled “Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric/GEJ Cancer” was presented today at the ASCO Gastrointestinal Cancer Symposium in San Francisco. The poster (Board J1, Abstract #91) can be found online at Five Prime Therapeutics Scientific Publications. “Gastric cancer with FGFR2b overexpression or FGFR2 gene amplification is associated with a poor prognosis for patients with advanced disease,” said Helen Collins, M.D., senior vice president and chief medical officer of Five Prime.

  • GlobeNewswirelast month

    Consolidated Research: 2019 Summary Expectations for Southern, Exelon, PriceSmart, Five Prime Therapeutics, Digi International, and Voyager Therapeutics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Jan. 16, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line
    American City Business Journalslast month

    Peninsula biotech sheds 20% of jobs to focus on drugs closer to finish line

    The 17-year-old biotech company, a big player in antibody drug research and development, will focus its cash on a maturing pipeline of experimental drugs while letting go of some longtime employees.

  • Business Wirelast month

    Five Prime Announces Restructuring to Focus on Clinical Development and Later-Stage Research Priorities

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today a corporate restructuring to focus resources on its development pipeline, comprising five clinical-stage cancer programs in various solid tumor types and addressing multiple cell types in the tumor microenvironment. “While we are on track for multiple data read-outs and potential phase advances from our pipeline in 2019, the Executive Team and Board felt it was necessary to sharpen our focus on our current clinical programs and the advancement of our later-stage research initiatives,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics.

  • Business Wirelast month

    Five Prime Therapeutics Announces Two Poster Presentations at the 2019 Gastrointestinal Cancers Symposium

    – Phase 1 Results from the Phase 1/3 FIGHT Study Evaluating Bemarituzumab and mFOLFOX6 in Advanced Gastric and Gastric Esophageal Junction Cancer –

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

    M&A momentum is building in the pharma space, with more deals announced last week, including Eli Lilly And Co (NYSE: LLY )'s $8-billion move to acquire Loxo Oncology Inc (NASDAQ: LOXO ). The following ...

  • Business Wire2 months ago

    Five Prime Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 37th Annual J.P.

  • Business Wire3 months ago

    Five Prime Therapeutics Announces Changes to its Board of Directors

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today changes to its Board of Directors. Mr. Mark McDade, who has served as a member of Five Prime’s Board of Directors since July 2006 and Lead Independent Director since March 2016, will retire from the Board effective November 30, 2018.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool3 months ago

    3 Top Biotech Stocks to Buy Right Now

    Ignoring these promising biotech stocks could be a mistake.

  • Business Wire3 months ago

    Five Prime Therapeutics to Present at 30th Annual Piper Jaffray Healthcare Conference

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference, November 28, 2018 at 11:10 am ET.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of FPRX earnings conference call or presentation 6-Nov-18 9:30pm GMT

    Q3 2018 Five Prime Therapeutics Inc Earnings Call

  • Business Wire3 months ago

    Five Prime Therapeutics Initiates Patient Dosing in a Phase 1 Clinical Trial of FPT155, a First-in-Class CD80 Fusion Protein

    Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced it initiated patient dosing in a Phase 1 clinical trial of FPT155, a first-in-class CD80 fusion protein. “We are pleased to initiate patient dosing for FPT155, our first-in-class CD80-Fc fusion protein, which is engineered to activate T cells through multiple pathways,” said Helen Collins, M.D., Senior Vice President and Chief Medical Officer of Five Prime. “In vivo, FPT155 demonstrates strong single-agent activity in multiple preclinical models, including some that are generally resistant to immune-modulating therapy.

  • Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more
    American City Business Journals3 months ago

    Health Care Digest: A big Berkeley bio incubator, Apple's clinical trial help and more

    Our weekly guide to what's happening in the biotech, medical devices, diagnostics and hospital space.